| A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) (NCT07636811) | Alnylam Pharmaceuticals | 2026-08-31 |
| HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB (NCT07575308) | Alnylam Pharmaceuticals | 2026-07-30 |
| A Study to Evaluate ALN-6222 in Participants With Obesity (NCT07624071) | Alnylam Pharmaceuticals | 2026-06-04 |
| A Study to Evaluate ALN-2232 in Participants With Obesity (NCT07463846) | Alnylam Pharmaceuticals | 2026-03-02 |
| A Study to Evaluate ALN-4915 in Adult Healthy Volunteers (NCT07535606) | Alnylam Pharmaceuticals | 2026-03-02 |
| A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus (NCT07465224) | Alnylam Pharmaceuticals | 2026-01-15 |
| DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting (NCT07358078) | Alnylam Pharmaceuticals | 2026-01-09 |
| A Study to Evaluate ALN-4285 in Adult Healthy Volunteers (NCT07295717) | Alnylam Pharmaceuticals | 2025-12-12 |
| TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NCT07223203) | Alnylam Pharmaceuticals | 2025-12-12 |
| A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease (NCT07214727) | Alnylam Pharmaceuticals | 2025-10-15 |
| Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (NCT07181109) | Alnylam Pharmaceuticals | 2025-09-22 |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (NCT07052903) | Alnylam Pharmaceuticals | 2025-07-02 |
| A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM (NCT06845202) | Alnylam Pharmaceuticals | 2025-03-03 |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma (NCT06600321) | Alnylam Pharmaceuticals | 2024-12-30 |
| A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (NCT06679946) | Alnylam Pharmaceuticals | 2024-12-03 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) (NCT06659640) | Alnylam Pharmaceuticals | 2024-11-07 |
| A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers (NCT06675565) | Alnylam Pharmaceuticals | 2024-11-05 |
| A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease (NCT06585449) | Alnylam Pharmaceuticals | 2024-10-14 |
| A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension (NCT06423352) | Alnylam Pharmaceuticals | 2024-06-05 |
| A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (NCT06393712) | Alnylam Pharmaceuticals | 2024-05-17 |
| Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy (NCT06360289) | Alnylam Pharmaceuticals | 2024-04-25 |
| Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (NCT06272487) | Alnylam Pharmaceuticals | 2024-02-29 |
| A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM (NCT05761301) | Alnylam Pharmaceuticals | 2023-03-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects (NCT05661916) | Alnylam Pharmaceuticals | 2023-01-16 |
| A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout (NCT05256810) | Alnylam Pharmaceuticals | 2022-02-25 |
| A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD (NCT05231785) | Alnylam Pharmaceuticals | 2022-02-04 |
| A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels (NCT05161936) | Alnylam Pharmaceuticals | 2022-01-27 |
| BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) (NCT04982393) | Alnylam Pharmaceuticals | 2021-12-13 |
| Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (NCT05103332) | Alnylam Pharmaceuticals | 2021-11-05 |
| A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (NCT04936035) | Alnylam Pharmaceuticals | 2021-07-07 |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) (NCT04883905) | Alnylam Pharmaceuticals | 2021-04-26 |
| ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (NCT04561518) | Alnylam Pharmaceuticals | 2020-11-23 |
| A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) (NCT04565717) | Alnylam Pharmaceuticals | 2020-10-09 |
| Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program (NCT05040373) | Alnylam Pharmaceuticals | 2020-08-01 |
| A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (NCT04152200) | Alnylam Pharmaceuticals | 2020-01-21 |
| A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation (NCT04201418) | Alnylam Pharmaceuticals | 2019-12-18 |
| HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (NCT04153149) | Alnylam Pharmaceuticals | 2019-11-26 |
| A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) (NCT03841448) | Alnylam Pharmaceuticals | 2019-09-30 |
| APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) (NCT03997383) | Alnylam Pharmaceuticals | 2019-09-04 |
| A Study to Evaluate ALN-AGT01 in Patients With Hypertension (NCT03934307) | Alnylam Pharmaceuticals | 2019-05-01 |
| A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (NCT03905694) | Alnylam Pharmaceuticals | 2019-04-22 |
| Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant (NCT03862807) | Alnylam Pharmaceuticals | 2019-03-27 |
| HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) (NCT03759379) | Alnylam Pharmaceuticals | 2019-02-14 |
| A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease (NCT03774784) | Alnylam Pharmaceuticals | 2019-01-29 |
| A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (NCT03767829) | Alnylam Pharmaceuticals | 2018-12-05 |
| A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (NCT03681184) | Alnylam Pharmaceuticals | 2018-11-27 |
| INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP (NCT03547297) | Alnylam Pharmaceuticals | 2018-05-29 |
| A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP) (NCT03505853) | Alnylam Pharmaceuticals | 2018-04-26 |
| An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 (NCT03350451) | Alnylam Pharmaceuticals | 2018-04-04 |
| ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) (NCT03338816) | Alnylam Pharmaceuticals | 2017-11-16 |
| A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome (NCT03303313) | Alnylam Pharmaceuticals | 2017-09-19 |